SLU-PP-332 500 mcg - 100 tablets - Advanced and Effective Delivery
SLU-PP-332 is a powerful preclinical āexercise mimeticā with metabolic, mitochondrial, cardiac, and renal benefits. While highly promising in animal studies, it remains experimentalāwith no current approval or human safety data. Itās strictly a research tool at this point.
SLU-PP-332, a synthetic agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ), especially acting more potently at ERRα (ECā ā ā 98 nM) (Wikipedia):
Main Benefits (Preclinical Findings)
1. Metabolic Health & Fat Reduction
- Significantly reduces body weight (~18ā24%) and white adipose tissue mass (~30ā35%) in obese mouse models (Wikipedia).
- Enhances glucose metabolism: ~40% improvement in glucose tolerance, ~25ā30% reduction in fasting insulin levels (Wikipedia).
- Lowers blood lipids and improves liver healthāreducing hepatic steatosis and inflammation.
2. Exercise Mimetic & Muscular Endurance
- Mimics aerobic exercise at the molecular level by activating ERR-mediated pathways.
- Increases mitochondrial density (up to ~1.8-fold) in skeletal muscles and upregulates GLUT4, enhancing glucose uptake and oxidation (Wikipedia).
- Enhances running capacity by 30ā40%, shifts muscle fiber composition toward oxidative types, and increases vascular density (Wikipedia).
3. Mitochondrial & Aging-Related Benefits
- Restores mitochondrial respiration in aged kidney and liver tissues.
- Reduces markers of inflammation (e.g., IL-6, TNF-α), oxidative damage, and fibrosis; improves autophagy and mitophagy (Wikipedia).
4. Cardioprotective Effects
- In models of heart failure and ischemia-reperfusion, it:
- Preserves cardiac contractility
- Reduces cardiomyocyte death
- Enhances fatty acid oxidation and energetics
- Attenuates pathological cardiac remodeling (Wikipedia).
5. Renal Protective Effects
- Reverses aging-associated kidney damage; improves mitochondrial function, reduces inflammation, and improves structural integrity via cGASāSTING and STAT3 signaling pathways.
Mechanism of Action
SLU-PP-332 activates ERRs, especially ERRα, which regulate genes related to:
- Mitochondrial biogenesis (via TFAM, PGC-1α)
- Oxidative phosphorylation
- Fatty acid metabolism (e.g., via CPT1, MCAD)
- Energy sensing and endurance pathways (e.g., AMPK activation) (Wikipedia).
These effects essentially replicate many of the beneficial adaptations from aerobic trainingāeven without actual exercise.
Status & Caveats
|
Aspect |
Details |
|
Research Stage |
Fully preclinicalātested only in cell and animal models; no human clinical trials yet (Wikipedia). |
|
Safety Profile |
Limited data; mild hyperthermia, increased heart rate, and transient liver enzyme elevations observed in animal studies at higher doses (Wikipedia). |
|
Limitations |
Off-target activity may occur at higher concentrations (>5 μM); complex synthesis and pharmacokinetic challenges like twice-daily dosing required (Wikipedia). |
Summary of Potential Benefits (Based on Preclinical Models)
- Promotes weight loss and reduces fat mass
- Improves insulin sensitivity and glucose metabolism
- Mimics exercise adaptations: boosts endurance, mitochondrial function, and oxidative metabolism
- Supports aging tissue health: improves mitochondrial function in kidney and liver, reduces inflammation
- Protects cardiac function in disease models
Takeaway
SLU-PP-332 is a powerful preclinical āexercise mimeticā with metabolic, mitochondrial, cardiac, and renal benefits. While highly promising in animal studies, it remains experimentalāwith no current approval or human safety data. Itās strictly a research tool at this point.
SLU-PP-332 tablets (500 mcg):
Other Ingredients:
Microcrystalline Cellulose (MCC) ā filler/diluent
Lactose Monohydrate ā filler
Magnesium Stearate ā lubricant
Colloidal Silicon Dioxide ā flow aid
1 tablet 1x per day, in the morning, 5 days on 2 days off per week, or as directed by your personal experience or by your healthcare provider.
Product Reviews
No reviews available for this product.